How have ORGS shares performed in 2024?

Orgenesis' stock was trading at $0.5007 at the beginning of 2024. Since then, ORGS stock has decreased by 0.1% and is now trading at $0.50. View the best growth stocks for 2024 here .

When is Orgenesis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ORGS earnings forecast .

How were Orgenesis' earnings last quarter?

Orgenesis Inc. (NASDAQ:ORGS) issued its quarterly earnings results on Friday, August, 11th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.21. The company earned $6.98 million during the quarter. Orgenesis had a negative net margin of 91.25% and a negative trailing twelve-month return on equity of 107.27%.

How do I buy shares of Orgenesis?

Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Does Orgenesis have any subsidiaries?

The following companies are subsidiares of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc. Read More

NASDAQ:ORGS

Orgenesis (ORGS) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free ORGS Stock Alerts

$0.50

-0.01 (-1.96%)

(As of 04/18/2024 ET)

Compare

Today's Range: $0.50
▼
$0.51
50-Day Range: $0.30
▼
$0.90
52-Week Range: $0.25
▼
$1.50

Volume: 26,689 shs
Average Volume: 420,794 shs
Market Capitalization: $17.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Get Orgenesis alerts:

Orgenesis MarketRank™ Stock Analysis

Analyst Rating: N/A
Upside/Downside: N/A
Short Interest: Healthy
0.87% of Shares Sold Short
Dividend Strength: N/A
Sustainability: -1.49
Upright™ Environmental Score
News Sentiment: 0.21
Based on 3 Articles This Week
Insider Trading: Acquiring Shares
$22,483 Bought Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.06 out of 5 stars

Medical Sector

609th out of 918 stocks

Pharmaceutical Preparations Industry

276th out of 428 stocks

N/A

Analyst's Opinion

Consensus Rating
There is not enough analysis data for Orgenesis.

5.0

Short Interest

Percentage of Shares Shorted
0.87% of the outstanding shares of Orgenesis have been sold short.
Short Interest Ratio / Days to Cover
Orgenesis has a short interest ratio ("days to cover") of 1.9, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Orgenesis has recently decreased by 6.98%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Orgenesis does not currently pay a dividend.
Dividend Growth
Orgenesis does not have a long track record of dividend growth.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Orgenesis has received a 66.16% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Clinical research services for infectious diseases", "Gene therapy medication", and "Clinical research services for physiological diseases " products. See details.
Environmental Sustainability
The Environmental Impact score for Orgenesis is -1.49.

2.3

News and Social Media Coverage

News Sentiment
Orgenesis has a news sentiment score of 0.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.53 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 3 news articles for Orgenesis this week, compared to 0 articles on an average week.
Search Interest
Only 1 people have searched for ORGS on MarketBeat in the last 30 days. This is a decrease of -88% compared to the previous 30 days.
MarketBeat Follows
2 people have added Orgenesis to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orgenesis insiders have bought more of their company's stock than they have sold. Specifically, they have bought $22,483.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 7.14% of the stock of Orgenesis is held by insiders.
Percentage Held by Institutions
Only 22.56% of the stock of Orgenesis is held by institutions.

0.6

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Orgenesis is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Orgenesis is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Orgenesis has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad InvestorPlace

New crypto project uncovers 2,050% in 65 days

During the event on Tuesday, April 23 at 10 am ET, I’ll be giving away the name and ticker symbol of crypto that could surge in price. I believe it will be the best performing crypto of 2024.

Just click here to sign up and be among the first to get it.

About Orgenesis Stock (NASDAQ:ORGS)

Orgenesis Inc., a biotech company, focusing on cell and gene therapies worldwide. The company develops a Point of Care (POCare) platform that includes a pipeline of licensed POCare therapeutics that are processed and produced in closed automated POCare technology systems across a collaborative POCare network. It focuses on autologous therapies, with processes and systems that are developed for each therapy using a closed and automated processing system approach that is validated for compliant production near the patient at their point of care for treatment of the patient. The company was formerly known as Business Outsourcing Service, Inc. and changed its name to Orgenesis Inc. in August 2011. Orgenesis Inc. was incorporated in 2008 and is based in Germantown, Maryland.

ORGS Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ORGS Stock News Headlines

April 17, 2024 | investing.com

Orgenesis secures $2.3 million investment and strategic partnership

April 17, 2024 | finanznachrichten.de

Orgenesis Inc.: Orgenesis Provides Year End Business Update

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 15, 2024 | globenewswire.com

Orgenesis Provides Year End Business Update

April 11, 2024 | investing.com

Germfree partners with Orgenesis to enhance CGT production

April 10, 2024 | globenewswire.com

Germfree and Orgenesis Announce Asset Purchase and Strategic Partnership Intended to Revolutionize Cell and Gene Therapy Through Decentralized Production and Global Accessibility

March 18, 2024 | globenewswire.com

Vered Caplan, CEO of Orgenesis, to Present at the Bioprocessing Summit Europe Conference

March 13, 2024 | globenewswire.com

Orgenesis Consortium Awarded €1.5M EUR Grant from the Walloon Government in Belgium for EXOFASTTRACK Project Dedicated to Accelerated Development of Multiple Therapeutic Exosomes

April 19, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 4, 2024 | globenewswire.com

Orgenesis Inc. Announces $2.3 Million Private Placement

February 29, 2024 | globenewswire.com

Orgenesis Consortium Awarded €2.0M EUR Grant from Walloon Government in Belgium for MAIDAM AI Project for Monitoring Decentralized ATMP Manufacturing

February 23, 2024 | finance.yahoo.com

Orgenesis Inc. (ORGS)

February 22, 2024 | morningstar.com

Orgenesis Inc ORGS

January 31, 2024 | msn.com

EXCLUSIVE: Orgenesis Acquires Control of Octomera, Takes One Step Closer To Progressing Its Decentralized Immuno-Oncology Portfolio To Clinic

January 31, 2024 | finance.yahoo.com

Orgenesis Acquires Control of Octomera with the Goal of Progressing its Decentralized Immuno-Oncology Portfolio to Clinic

January 8, 2024 | finance.yahoo.com

Orgenesis Inc. (ORGS) Stock Historical Prices & Data - Yahoo Finance

November 22, 2023 | finance.yahoo.com

Analysts Expect Orgenesis Inc. (NASDAQ:ORGS) To Breakeven Soon

November 15, 2023 | finanznachrichten.de

Orgenesis Inc.: Orgenesis Provides Business Update for the Third Quarter of 2023

November 14, 2023 | finance.yahoo.com

Orgenesis Ranked No. 171st Fastest-Growing Company in North America on the 2023 Deloitte Technology Fast 500 TM

November 13, 2023 | finance.yahoo.com

Orgenesis Provides Business Update for the Third Quarter of 2023

November 8, 2023 | finance.yahoo.com

Orgenesis Inc. Announces Pricing of $1.1 Million Registered Direct Offering

November 5, 2023 | forbes.com

6 Secrets Of Organizations That Successfully Adapt To Change

November 2, 2023 | finance.yahoo.com

Orgenesis Announces Expanded Partnership Between Octomera and UC Davis Through CIRM Grant Funding

October 31, 2023 | finanznachrichten.de

Orgenesis Inc.: Orgenesis Announces Withdrawal of Proposed Public Offering

October 30, 2023 | finance.yahoo.com

Orgenesis Announces Withdrawal of Proposed Public Offering

October 30, 2023 | finance.yahoo.com

Orgenesis Announces Proposed Underwritten Public Offering

September 21, 2023 | stockhouse.com

CGT Global and Octomera Enter Agreement to Expand Cell & Gene Therapy Development and Patient Access Across the United States

See More Headlines

Receive ORGS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orgenesis and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 8/11/2023
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ORGS
CUSIP: N/A
CIK: 1460602
Web: www.orgenesis.com
Phone: (480) 659-6404
Fax: N/A
Employees: 167
Year Founded: 2008

Profitability

EPS (Most Recent Fiscal Year): ($0.91)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,890,000.00
Net Margins: -91.25%
Pretax Margin: -75.89%
Return on Equity: -107.27%
Return on Assets: -35.64%

Debt

Debt-to-Equity Ratio: 1.48
Current Ratio: 0.61
Quick Ratio: 0.61

Sales & Book Value

Annual Sales: $530,000.00
Price / Sales: 32.40
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.14 per share
Price / Book: 0.44

Miscellaneous

Outstanding Shares: 34,340,000
Free Float: 29,601,000
Market Cap: $17.17 million
Optionable: Optionable
Beta: 1.07

Social Links

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Key Executives

Ms. Vered Caplan M.Sc. (Age 55)
Chairperson of the Board, CEO & President
Comp: $335.97k
Prof. Sarah Ferber Ph.D. (Age 70)
Founder & Chief Scientific Officer
Comp: $268.32k
Mr. Victor Miller (Age 54)
Chief Financial Officer
Pierre Lammeretz
Interim Chief Operating Officer
Dr. Shimon Hassin Ph.D.
Chief Technology Officer
Mr. Evan Fishman
Chief Financial Officer of Orgenesis Biotech
Mr. Joseph Carpinelli
Chief Financial Officer of Octomera

Key Competitors

View All Competitors

Insiders

View All Insider Transactions

ORGS Stock Analysis - Frequently Asked Questions

How have ORGS shares performed in 2024?: Orgenesis' stock was trading at $0.5007 at the beginning of 2024. Since then, ORGS stock has decreased by 0.1% and is now trading at $0.50.
View the best growth stocks for 2024 here.
When is Orgenesis' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ORGS earnings forecast.
How were Orgenesis' earnings last quarter?: Orgenesis Inc. (NASDAQ:ORGS) issued its quarterly earnings results on Friday, August, 11th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of $0.06 by $0.21. The company earned $6.98 million during the quarter. Orgenesis had a negative net margin of 91.25% and a negative trailing twelve-month return on equity of 107.27%.

How do I buy shares of Orgenesis?: Shares of ORGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.
Does Orgenesis have any subsidiaries?: The following companies are subsidiares of Orgenesis: Koligo Therapeutics, and Tamir Biotechnology Inc.
Read More

This page (NASDAQ:ORGS) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial